The role of transforming growth factor-β in suppression of hepatic metastasis from colon cancer

HPB

Volumn 12, Issue 7, 2010, Pages 498-506

  Are, Chandrakanth ^a,b   Simms, Neka ^b   Rajupt, Ashwani ^c   Brattain, Michael ^b  

^a Department of Surgery   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Basic science < liver; Colorectal metastases < liver

Indexed keywords

RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER METASTASIS; LUNG METASTASIS; MALE; METASTASIS; MOUSE; NONHUMAN; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

EID: 77956893381     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2010.00219.x     Document Type: Article

References (35)

1. Chiang AC, Massague J. (2008) Molecular basis of metastasis. N Engl J Med 359:2814-2823.
2. Mehlen P, Puisieux A. (2006) Metastasis: A question of life or death. Nat Rev Cancer 6:449-458.
3. Wang J, Yang L, Yang J, Kuropatwinski K, Wang W, Liu XQ et al. (2008) Transforming growth factor-β induces apoptosis through repressing the phosphoinositide 3-kinase/Akt/survivin pathway in colon cancer cells. Cancer Res 68:3152-3160.
4. Siegel PM, Massague J. (2003) Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 3:807-821.
5. Derynck R, Zhang YE. (2003) Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425:577-584.
6. Bierie B, Moses HL. (2006) Tumour microenvironment: TGF-β: The molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6:506-520.
7. Korpal M, Kang Y. (2010) Targeting the transforming growth factor-β signalling pathway in metastatic cancer. Eur J Cancer 46:1232-1240.
8. Gatza CE, Oh SY, Blobe GC. (2010) Role for the type III TGF-β receptor in human cancer. Cell Signal 22:1163-1174.
9. Joshi A, Cao D. (2010) TGF-β signalling, tumour microenvironment and tumour progression: The butterfly effect. Front Biosci 1:180-194.
10. Ikushima H, Miyazono K. (2010) Cellular context-dependent 'colours' of transforming growth factor-β signalling. Cancer Sci 101:306-312.
11. Ammanamanchi S, Kim SJ, Sun LZ, Brattain MG. (1998) Induction of transforming growth factor-β receptor type II expression in oestrogen receptor-positive breast cancer cells through SP1 activation by 5-aza-2?- deoxycytidine. J Biol Chem 273:16527-16534.
12. Kim SJ, Im YH, Markowitz SD, Bang YJ. (2000) Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis. Cytokine Growth Factor Rev 11:159-168.
13. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J et al. (1995) Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268:1336-1338.
14. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K. (2001) Transforming growth factor-β1 level correlates with angiogenesis, tumour progression, and prognosis in patients with non-small cell lung carcinoma. Cancer 91:964-971.
15. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S et al. (1996) High levels of transforming growth factor-β1 in patients with colorectal cancer: Association with disease progression. Gastroenterology 110:375-382.
16. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M et al. (1999) The expression of transforming growth factor-β1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 86:1455-1462.
17. Juarez P, Guise TA. (2010) TGF-β pathway as a therapeutic target in bone metastasis. Curr Pharm Des 16:1301-1312.
18. Zhong Z, Carroll KD, Policarpio D, Osborn C, Gregory M, Bassi R et al. (2010) Anti-transforming growth factor-β receptor II antibody has therapeutic efficacy against primary tumour growth and metastasis through multi-effects on cancer, stroma and immune cells. Clin Cancer Res 15:1191-1205.
19. Pasche B, Knobloch TJ, Bian Y, Liu J, Phukan S, Rosman D et al. (2005) Somatic acquisition and signalling of TGFBR1*6A in cancer. JAMA 294:1634-1646.
20. Padua D, Zhang XH,Wang Q, Nadal C, Gerald WL, Gomis RR et al. (2008) TGF-β primes breast tumours for lung metastasis seeding through angiopoietin-like 4. Cell 133:66-77.
21. Chantret I, Barbat A, Dussaulx E, Brattain MG, Zweibaum A. (1988) Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: A survey of twenty cell lines. Cancer Res 48:1936-1942.
22. Jiang D, Yang H, Willson JK, Liang J, Humphrey LE, Zborowska E et al. (1998) Autocrine transforming growth factor-a provides a growth advantage to malignant cells by facilitating re-entry into the cell cycle from suboptimal growth states. J Biol Chem 273:31471-31479.
23. Rajput A, Koterba AP, Kreisberg JI, Foster JM, Willson JK, Brattain MG. (2007) A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. Cancer Res 67:665-673.
24. Ye SC, Foster JM, Li W, Liang J, Zborowska E, Venkateswarlu S et al. (1999) Contextual effects of transforming growth factor-β on the tumorigenicity of human colon carcinoma cells. Cancer Res 59:4725-4731.
25. Sharkey RM, Primus FJ, Goldenberg DM. (1980) Comparison of the sensitivity of the indirect, antibody-conjugated and the triple-bridge immunoperoxidase methods for immunohistochemical detection of carcinoembryonic antigen. Histochemistry 66:35-42.
26. Guo XN, Rajput A, Rose R, Hauser J, Beko A, Kuropatwinski K et al. (2007) Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model. Cancer Res 67:5851-5858.
27. Endl E, Kausch I, Baack M, Knippers R, Gerdes J, Scholzen T. (2001) The expression of Ki-67, MCM3 and p27 defines distinct subsets of proliferating, resting, and differentiated cells. J Pathol 195:457-462
28. Gavrieli Y, Sherman Y, Ben-Sasson SA. (1992) Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation. J Cell Biol 119:493-501.
29. Vermeulen K, Van Bockstaele DR, Berneman ZN. (2005) Apoptosis: Mechanisms and relevance in cancer. Ann Hematol 84:627-639.
30. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods 184:39-51.
31. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P et al. (1992) Features of apoptotic cells measured by flow cytometry. Cytometry 13:795-808.
32. Hayashi K, Tanaka M, Shimada T, Miwa M, Sugimura T. (1983) Size and shape of poly(ADP-ribose): Examination by gel filtration, gel electrophoresis and electron microscopy. Biochem Biophys Res Commun 112:102-107.
33. Massagué J. (2008) A very private TGF-β receptor embrace. Mol Cell 29:149-150.
34. Welm AL. (2008) TGF-β primes breast tumour cells for metastasis. Cell 133:27-28.
35. Hanahan D, Weinberg RA. (2000) The hallmarks of cancer. Cell 100:57-70.